JB Chemicals & Pharmaceuticals Limited has released its Business Responsibility and Sustainability Report for the financial year 2025-26, highlighting significant contributions from international markets. The company has reported that exports account for 35% of its total turnover, underscoring its strong presence in global markets.
The report details the company’s operations, revealing that JB Chemicals serves over 150 million patients annually within India, with a notable presence in the cardiology segment. The company considers Russia and South Africa as key markets alongside India. It exports finished formulations to more than 40 countries, including the United States, and is recognised as a global leader in the production of medicated and herbal lozenges.
The company’s operations include eight manufacturing facilities across India, all certified by major international regulatory authorities. These facilities include a dedicated unit for lozenges, which contributes to JB Chemicals’ standing among the top five lozenge manufacturers worldwide.
In terms of workforce, JB Chemicals employs a total of 5,470 people, with a male-to-female ratio of approximately 89.63% to 10.37% among employees. The company also employs 2,436 workers, with a similar gender distribution. The report highlights the company’s commitment to inclusivity, with provisions for differently abled employees and workers.
JB Chemicals’ sustainability efforts are guided by several principles, including conducting business with integrity, providing sustainable and safe goods, promoting employee well-being, and respecting human rights and the environment. The company aims to influence public and regulatory policy responsibly and transparently, promote inclusive growth, and engage with consumers responsibly.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).